Lifeward Shuffles Leadership Amid Strong Commercial Momentum
Event summary
- Josh Hexter appointed Interim CEO of Lifeward effective September 1, 2026, succeeding Mark Grant.
- Rami Aviram named CFO, effective November 1, 2026.
- Q2 2026 revenue up 16% YoY to $6.6M, with ReWalk® sales up 13% and AlterG® revenue up 25%.
- Mark Grant departs after establishing commercial strategy, including reimbursement and distribution models.
The big picture
Lifeward's leadership transition comes as the company scales its rehabilitation business, leveraging established reimbursement and distribution models. The appointments of Hexter and Aviram signal a focus on capital-efficient growth, aligning with broader industry trends toward diversified biomedical innovation. With Q2 2026 revenue at $6.6M, the company is positioning itself for further expansion into therapeutic platforms beyond neurorehabilitation.
What we're watching
- Execution Risk
- Whether Hexter can sustain the 16% YoY revenue growth amid leadership transition.
- Strategic Expansion
- The pace at which Lifeward diversifies beyond neurorehabilitation into high-value therapeutic platforms.
- Financial Stability
- How Aviram's finance expertise will impact Lifeward's capital efficiency and growth strategy.